Intro
Polycystic ovary syndrome (PCOS), one of the most
common causes of an-ovulatory, is a heterogeneous
endocrine disorder in infertile women, affecting up to
6-20% of women of reproductive age ( 1 ).
PCOS is confirmed by existing at least two of three
special features based on the Rotterdam criteria:
clinical/ biochemical evidence of hyperandrogenism,
oligomenorrhea/ anovulation, and polycystic ovaries ( 2 ).
A wide variety of genetic alterations in differential tissues
and cell types impact normal follicular development in
this syndrome. Imbalanced follicle-stimulating hormone
(FSH), luteinizing hormone (LH), and some key factors
that are involved in the inappropriate progression of
folliculogenesis are the main molecular features associated
with impaired and arrested development of the germinal
vesicle stage of oocytes toward the dominant and mature
follicles in polycystic ovaries ( 3 , 4 ).
The delicate communication process between different
types of cells in the mammalian follicles, namely oocyte
and its surrounding somatic cells, granulosa (GCs), and
cumulus cells (CCs), has a pivotal impact on the oogenesis
process, oocyte maturation, cumulus expansion, and
ovulation ( 5 , 6 ). Paracrine signals of the oocyte are the
potent stimulators in GCs/CCs, which regulate the above
physiological processes and consequently affect female
fertility ( 7 ).
Among the secreted factors by the oocyte or follicle somatic cells, transforming growth
factor-beta (TGF-β) superfamily and its members, including anti-mullerian hormone
( AMH ), growth and differentiation factor 9 ( GDF9 ), and
bone morphogenetic protein 15 ( BMP15 ) which are expressed in follicular
stage-related manner, have been implicated as key regulators in various aspects of
intra-ovarian development ( 8 ). On the other hand, alteration in expression of these factors,
especially AMH , is related to pathological ovarian conditions, such as PCOS
and Endometriosis ( 9 ).
AMH is now a quantitative marker of ovarian reserve as
well as a diagnostic factor for PCOS ( 10 ). TGF-β family
members bind to their receptors in GCs/CCs which induces
a cascade of several downstream protein-coding genes.
Even though GCs are differentiated into CCs and both of
them have a common progenitor during folliculogenesis,
the mentioned genes show different expression and even
regulation patterns in those specialized cell types ( 11 , 12 ).
Based on previous studies, alterations in the gene
expression pattern of granulosa-cumulus cells play a
definite role in the impaired final maturation of antral
follicles to later-stage growth, which is one of the main
contributing factors and underlying causes of polycystic
ovaries ( 13 ).
AMH is secreted from ovarian cells in the growing
follicles and can regulate the FSH-dependent follicle
development. Previous studies showed that the expression
and secretion of AMH from granulosa-cumulus cells are
increased in preovulatory follicles, which contain atretic
oocytes ( 14 , 15 ).
GDF-9 and BMP-15, as other members of the TGF-β
superfamily, are known as growth promoters during normal
folliculogenesis ( 16 ). A study of intraovarian interactions,
regulatory mechanisms, and possible abnormalities
which interfere with the balance between these molecular
factors in patients suffering PCOS compared to women
with normal oogenesis can provide a better overview of
controlling and monitoring ovarian function that may be
resulted in improving the fertility of such patients.
This study aimed to investigate the mRNA expression profile of BMP15, GDF9, AMH
genes, and their respective receptors, which include: BMPR1A, BMPR1B , and
BMPR2 , in GCs and CCs of PCOS patients, compared to women with normal
oogenesis undergoing controlled ovarian stimulation (COS) treatment cycles.
Results
Table 2 presents all the demographic data. Age, BMI,
and duration of infertility were similar between the
PCOS and control groups (P>0.05). However, there were
significant differences among them considering the main
PCOS features and characteristics, such as the ratio of LH/
FSH, LH and AMH levels ( Table 2 ). The PCOS subjects
showed higher LH level than normo-ovulatory females
(control group) (P<0.01).
Demographic information
The results are reported as mean ± SD. AMH; Anti-mullerian hormone, BMI; Body mass index, FSH; Follicle-stimulating hormone, TSH; Thyroid stimulating
hormone, and *; P<0.05.
As shown in Figure 1 , all amplified RT-PCR products were at the expected size for
GDF9, BMP15, AMH, BMPR1B, BMPR1A , and BMPR2 genes.
In GCs isolated from PCOS subjects, an overexpression of AMH
(P<0.001) and BMPR1A (P0.001), BMP15, BMPR1B, and
BMPR2 gene expression were significantly decreased (P<0.001,
Fig .2A ).
On the other hand, CCs from PCOS patients display the same patterns as observed in
GCs genes expression increased expression of AMH (P<0.001) and
BMPR1A (P<0.038); decreased expression of GDF9
(P<0.001), BMP15 (P=0.005), BMPR1B
(P<0.004), and BMPR2 (P<0.001) mRNA significantly
( Fig .2B ).
Results of RT-PCR for mRNA expression of GDF9, BMP15, AMH, BMPR1B, BMPR1A , and
BMPR2 genes (DNA ladder 50 base pair). RT-PCR; Reverse
transcription polymerase chain reaction.
Expression level of GDF9, BMP15, AMH and their receptors in polycystic ovarian
syndrome (PCOS) women and control group. A. Gene expression of granulosa
cell from PCOS women compared to control group. B. Gene expression of
cumulus cells from PCOS women compared to control group.
Differential gene expression profile in granulosa compared to cumulus cells. A. Gene
expression profile in granulosa cells compared to cumulus cells in polycystic ovarian
syndrome (PCOS) group. B. Gene expression profile in granulosa cells
compared to cumulus cells in control groups.
Comparing CCs and GCs from PCOS patients
revealed GDF9, BMP15 (P<0.05) and AMH (P<0.001)
have higher expression in cumulus cells; in contrast,
BMPR1A (P<0.05) expression level is higher in GCs
of such patients ( Fig .3A ). On the other hand, BMP15
(P<0.001) and BMPR1B (P<0.03) are effe∆ively
expressed in normal granulosa cells compared to
normal CCs, and AMH (P<0.001) and GDF9 (P<0.001)
have higher mRNA expression in CCs of control than
PCOS patients ( Fig .3B ).
Discussion
The differential gene expression levels of AMH and its regulatory factors
that include BMP15 and GDF9 , as well as their primary
receptors: BMPR2, BMPR1B , and BMPR1A , were detected in
granulosa and cumulus cells in PCOS women compared to the control group. In addition, these
genes showed different expression patterns in two ovarian cells (GCs and CCs).
Granulosa cells show phenotypic heterogeneity in the
developing ovarian Follicle. During folliculogenesis, the
heterogeneous GC populations differentiate and divide
into mural GCs and CCs. Their function is associated
with their position in the follicles and proximity to
the oocyte resulting in different properties and gene
expression patterns ( 19 , 20 ). The mural GCs have a great
steroidogenic function, a high level of LH receptors, and
mainly are involved in the acquisition of signals from
outside Follicle; however, the cumulus cells provide
essential regulatory factors for oocytes to promote final
cytoplasmic and nuclear maturation ( 21 , 22 ).
The resumption of oocyte meiosis is regulated by activating some genes in the oocyte itself
and a broad signaling network in other follicular cells ( 23 ). The increased expression of
BMP15 and BMPR1B receptors in the periovulatory phase of
ovarian cells showed their implication in the ovulatory process. On the other hand, these
BMP proteins, the largest subfamily belonging to the TGFβ superfamily, regulate numerous
main biological processes in the ovarian follicle, including cell differentiation,
proliferation, and apoptosis ( 24 ). Also, the expression of BMPR1B is
correlated with serum oestradiol (E2) level in normal folliculogenesis ( 25 ). Alterations in
BMPs signaling are involved in some folliculogenesis disorders such as PCOS ( 24 ). In
Bmp15 knockout mice, uni- and bi-lateral cysts developed, ovulation rate
was decreased and female mice were subfertile due to reduced developmental potential of
oocytes and ovulation ( 26 ). The reduced expression of this ligand and its receptor in PCOS
patients, as shown in the present study, has revealed the association mechanism of
PCOS-related anovulation and impaired oocyte competency and maturation.
The study performed by Kedem-Dickman et al. ( 27 ) showed a reverse association between GC
-cumulus AMH expression and oocyte maturity in preovulatory follicles. It
means that corresponding GC-cumulus cells of the Germinal Vesicle oocyte stage express
higher AMH mRNA levels than the Metaphase stage ones. They suggested that AMH meiosis
inhibition, which had been confirmed previously ( 28 ), was the mechanism by which the oocytes
may fail to resume meiosis.
Some recent studies showed that high levels of AMH decrease the FSH receptors number and
reduces the sensitivity of GC to FSH, which consequently prevents the provoke activation of
critical genes in steroidogenesis processes such as P450scc and
CYP19A1 genes ( 29 ).
PCOS is a disease in which AMH has putative roles in
its pathophysiology ( 30 ). Usually, it is the first cause of
anovulation infertility in women ( 31 ). It seems that AMH
contributes to the mechanisms leading to antral follicle
arrest, anovulation, and oligomenorrhoea/ amenorrhoea
( 32 , 33 ). Taken together, these studies suggest that
increased AMH levels in PCOS women create an AMHdominated microenvironment, which counteracts the
action of FSH on follicles selection ( 34 ). The increased
pre-antral follicle number, which is the primary source of
AMH, is not merely contributing factor, but also elevated
AMH concentration in PCOS is largely due to increased
AMH production by individual follicles ( 35 ).
These studies have shown indirect confirmation of AMH’s role in PCOS. Further observations
elucidated the mechanism by which AMH expression is up-regulated in GCs. A
limited number of BMPs such as BMP15 can bind to BMPR1B and BMPR2 receptors, and the
activated receptors recognize SMAD1, which is translocated to the AMH promoter sequence.
This mechanism significantly causes the AMH expression induction in human
GCs ( 36 , 37 ). In our study, mRNA expression of BMP15 in cumulus cells of PCOS patients is
higher than in granulosa ones, and AMH expression was also higher in these
cells. However, when CCs/GCs of PCOS are compared to normal oogenesis ones, this pattern was
not observed. The high level of AMH expression in PCOS may be due to an
additional source of BMP15 secretion, especially from the corresponding oocyte, which could
induce AMH expression in CCs/GCs of such patients.
In PCOS, however, BMPR1A in GCs and GDF9, BMP15 and
AMH in CCs have a substantial expression. These distinct alterations in
the follicular microenvironment of PCOS patients may negatively interfere with
intra-follicular signals such as the follicle sensitivity to FSH, compromise the dominant
follicle selection and the other functions of the GC/CC cells from the viewpoint of the
oocyte maturation aspect and reproductive processes ( 38 , 39 ).
On the other hand, in ovarian cells, the most important
receptor for AMH is BMPR-1A. Therefore some members
of the TGF-β superfamily share their signaling pathway with
AMH, and target genes involved in folliculogenesis and GCs
differentiation could also be regulated by AMH ( 40 ).
To explore whether gene expression pattern is diverse between cumulus cells and granulosa
cells, we analyzed the expression profile. Data showed a differential overexpression of
GDF9, BMP15 , and AMH in infertile PCOS cumulus cells in
comparison to PCOS granulosa cells. However, AMH and GDF9
have the same pattern in normal cyclic cumulus cells, but BMP15 and
BMPR1B significantly decreased in granulosa cells of normal patients.
Therefore, the gene expression profile in both GC and CC cells showed interesting diversity.
Since the same antagonist protocol for ovarian stimulation was used in both PCOS and control
groups, the results were independent of the protocols.
Conclusions
To conclude, based on the previous results, increased gene expression of
AMH and BMPR1A and decreased gene expression of
GDF9, BMP15 , and BMPR1B may contribute to alterations in
the downstream pathway, which are involved in ovulatory function, follicular growth, and
oocyte maturation. The results of the current study are important for understanding the
mechanisms of follicular growth arresting and anovulation cycles in patients suffering from
PCOS. It will be considered to screen the epigenetic regulatory mechanism of the promoter
regions of the TGFβ family members and corresponding receptors in future studies.
Materials Methods
The case-control research was endorsed by the
Royan Institute Ethics Boards (IR.ACECR.ROYAN.
REC.1394.86). Thirty patients (15 PCOS patients with
infertility and 15 normo-ovulatory patients, 22≤age≤38
years old) were recruited to the study between November
2014 and April 2016 who underwent COS for IVF/ICSI
at the Infertility Clinic (Royan Institute, Iran). Informed
consent were obtained from all subjects.
Patients who met the following criteria were included in
the control group: absence of clinical/ biochemical signs of
hyperandrogenism or other endocrine diseases, polycystic
ovaries, diabetes, with regular menstrual cycles (26<cycle
length<32), having normal hormone profile (TSH, FSH,
and LH). All controls were undergoing ovarian stimulation
treatment due to their tubal factor infertility.
Rotterdam diagnostic criteria are routinely used for PCOS phenotyping which includes:
chronic oligo and/ or anovulation (35 days of cycle length), biochemical or
clinical evidence of hyperandrogenism (total testosterone concentration >0.5 ng/ml,
hirsutism, acne, and alopecia), and the presence of 12 or more ovarian cysts with 2-10 mm
diameter per cyst and/or ovarian volume ≥10 cm 3 on ultrasound (polycystic
ovaries).
Inclusion criteria for all women (PCOS and control) were including the first IVF/ICSI
cycle, ovarian stimulation by antagonist protocol, 22≤age≤38 years, and body mass index
(BMI) of 18-28 kg/m 2 . The severe male factor, including
oligo-astheno-teratozoospermia, retrieved sperm from testis, and semen freeze was excluded.
The semen was analyzed in accordance with the criteria of the 5 th edition of the
World Health Organization (WHO) in 2010.
All hormone tests (FSH and LH levels) were carried out on days 2 to 3 of the menstrual
cycle using electrochemiluminescence immunoassay kits (ECLIA kits, Roche Diagnostics GmbH,
Germany). Further evaluation of total testosterone concentrations in PCOS patients was
performed by using ELISA kits (Monobind Inc., USA), and serum AMH levels were assessed using
an electrochemiluminescence immunoassay by Elecsys ® and Cobas Immunoassay
Analyzers (Roche GmbH).
Down-regulation of the pituitary gland with GnRH
antagonist protocol [the administration of 75–150 IU
recombinant FSH (Gonal F; Merck Serono, or Puregon;
MSD, the Netherlands)] was done for all women up to the
day of human chorionic gonadotropin (hCG, Ovitrelle®,
Merck-Serono) injection. The COS was performed
considering the age of the women and the antral follicle
count (AFC).
The following steps were taken to isolate the follicular fluid and extract cumulus and
granulosa cells from collected cumulus-oocyte complex (COC) as described previously ( 17 ,
18 ). Briefly, follicular fluid (FF) was obtained after hCG injection (34-36 hours) during
ovarian puncture. COCs were collected from FF and repeatedly washed in culture medium
G1V5™ (Vitrolife AB, Sweden), then incubated at 37°C and 5% CO 2 . Just before
ICSI, the COC was denuded with hyaluronidase enzyme, then CCs washed in free enzyme
medium, and cold phosphate buffered saline (PBS), then the cells were pelleted by
centrifugation twice for 8 minutes at 3000 rpm; the pellet was snap-frozen in liquid
nitrogen then stored at -80°C ( 17 ).
After retrieval of COCs, aspirated FF was centrifuged
for 10 minutes at 2000 rpm. The clear supernatant
(without blood) was isolated, the pellet was solved in
Tyrode’s solution, and the suspension was added on
Sill select gradient and centrifuged at 3000 rpm for 13
minutes. Granulosa cells (The layer formed between
Sill select gradient and supernatant) were removed and
washed with 3 ml of DMEM / HamF12 medium 10%. In
the next step, the suspensions were centrifuged at 3000
rpm for 13 minutes. Afterward, the diluted hyaluronidase
enzyme was added, and the suspension was incubated for
3 minutes; a culture medium was added to neutralize the
effect of the enzyme, then the suspension was centrifuged
for 5 minutes at 1500 rpm; Red blood cell lysing buffer
was added to the cell suspension and incubated for 5
minutes, the solution was removed; granulosa cells were
taken for extraction of RNA.
Total RNA was extracted, then purified by removing
DNA genomic from the samples using the RNeasy Micro
Kit (Qiagen, cat. no: 74004) as per the ‘ ‘manufacturer’s
protocol which is also previously described ( 18 ).
After assessment of RNA quantity and quality by
using the NanoDrop spectrophotometer (NanoDrop 2000
spectrophotometer), cDNA was synthesized using 20
nanograms of total RNA according to QuantiTect Whole
Transcriptome Kit (Qiagen, Cat.No:207045) instruction
and stored at -20∘
C until molecular analysis.
For granulosa cells’ RNA extraction, TRIzol Reagent
(Sigma- Aldrich) was used following the ‘ ‘manufacturer’s
protocol. Genomic DNA contaminations were removed
from all extracted RNA samples by treating them by
DNaseI (Fermentas, Thermo Scientific, Germany).
DNase I enzyme was inactivated by incubation for
7 minutes at 65∘
C with EDTA (50 mM, Fermentas,
Germany). The purity of RNA was detected by NanoDrop
spectrophotometer to determine A260/A280 ratio. RNA
(1 µg) was reverse transcribed to cDNA using firststrand cDNA synthesis kit (K1632- Fermentas, Thermo
Scientific, Germany) instruction, then stored at -20∘
C
until molecular analysis.
A quantitative mRNA analysis was performed using the Step-One RT-PCR system for doing
qRT-PCR (Applied Biosystems, USA). All reactions were run in duplicate. Evaluation of mRNA
gene expression of GDF9, BMP15, AMH, BMPR1A, BMPR1B, BMPR2 between the
patient and control groups was done by calculation of ∆C t and 2 -∆Ct .
To perform this analysis, cDNAs were synthesized from granulosa and cumulus cells of
patients and healthy individuals. The qPCR was performed with humanspecific primers. The
product size and primer sets are listed in Table 1 . GAPDH primer was used
as a control gene expression. PCR products were visualized using Gel Red ZellBio, Germany)
staining and electrophoreses (1.7%-2% agarose, Paya pazhoh pars, Iran) under UV light by
Molecular Imager ® Gel Doc™ XR+ (BioRad, USA).
Sequence of the primers used for quantitative polymerase chain reaction (qPCR) experiments
Data obtained were analyzed using the Independent
Samples t test, using IBM SPSS software version 22.
The one-sample Kolmogorov-Smirnov (K-S) test was
used to determine whether the variables come from the
normal distribution in each group. Data are presented as
mean ± SD at the level of P<0.05.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.